Kitaeva Kristina V, Rutland Catrin S, Rizvanov Albert A, Solovyeva Valeriya V
Institute of Fundamental Medicine and Biology, Kazan Federal University, Kazan, Russia.
School of Veterinary Medicine and Science, University of Nottingham, Nottingham, United Kingdom.
Front Bioeng Biotechnol. 2020 Apr 9;8:322. doi: 10.3389/fbioe.2020.00322. eCollection 2020.
The development of new high-tech systems for screening anticancer drugs is one of the main problems of preclinical screening. Poor correlation between preclinical and data with clinical trials remains a major concern. The choice of the correct tumor model at the stage of testing provides reduction in both financial and time costs during later stages due to the timely screening of ineffective agents. In view of the growing incidence of oncology, increasing the pace of the creation, development and testing of new antitumor agents, the improvement and expansion of new high-tech systems for preclinical screening is becoming very important. The pharmaceutical industry presently relies on several widely used models, including two-dimensional models, three-dimensional models, microfluidic systems, Boyden's chamber and models created using 3D bioprinting. This review outlines and describes these tumor models including their use in research, in addition to their characteristics. This review therefore gives an insight into based testing which is of interest to researchers and clinicians from differing fields including pharmacy, preclinical studies and cell biology.
开发用于筛选抗癌药物的新型高科技系统是临床前筛选的主要问题之一。临床前数据与临床试验数据之间的相关性较差仍然是一个主要问题。在测试阶段选择正确的肿瘤模型，由于能够及时筛选出无效药物，从而在后期阶段减少了资金和时间成本。鉴于肿瘤学发病率不断上升，加快新型抗肿瘤药物的研发和测试速度，改进和扩展用于临床前筛选的新型高科技系统变得非常重要。制药行业目前依赖几种广泛使用的模型，包括二维模型、三维模型、微流控系统、博伊登小室以及使用3D生物打印创建的模型。本综述概述并描述了这些肿瘤模型，包括它们在研究中的应用及其特点。因此，本综述深入探讨了基础测试，这对来自不同领域（包括药学、临床前研究和细胞生物学）的研究人员和临床医生来说很有意义。
